Ruud van der Noll

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid et al. · Nature Cancer · 2022 · 120 citations · Full text

First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies

Pamela N. Münster, Rahul Aggarwal, David S. Hong et al. · Clinical Cancer Research · 2015 · 108 citations · Full text

Abstract LB-122: A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors

Jürgen Wolf, Patricia LoRusso, R.D. Camidge et al. · Cancer Research · 2012 · 49 citations

Pathology, Advanced Solid Tumors, Escalation Study +16

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer

Ruud van der Noll, Serena Marchetti, Neeltje Steeghs et al. · British Journal of Cancer · 2015 · 48 citations · Full text

AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies

Aurelius Omlin, Robert J. Jones, Ruud van der Noll et al. · Investigational New Drugs · 2015 · 48 citations

Urology, Oncology, Genitourinary Cancer +7